Complex dynamics of hepatitis B virus resistance to adefovir
暂无分享,去创建一个
[1] F. Zoulim,et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. , 2008, Journal of hepatology.
[2] P. Swaan,et al. Multi-level Analysis of Organic Anion Transporters 1, 3, and 6 Reveals Major Differences in Structural Determinants of Antiviral Discrimination* , 2008, Journal of Biological Chemistry.
[3] A. Lok,et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. , 2008, Journal of hepatology.
[4] Jean-Michel Pawlotsky,et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. , 2008, Gastroenterology.
[5] P. Lampertico,et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. , 2007, Gastroenterology.
[6] Michael D. Miller,et al. In Vitro Drug Susceptibility Analysis of Hepatitis B Virus Clinical Quasispecies Populations , 2007, Journal of Clinical Microbiology.
[7] Angeline Bartholomeusz,et al. Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.
[8] C. Yurdaydın,et al. A Novel Mutation Pattern Emerging during Lamivudine Treatment Shows Cross-Resistance to Adefovir Dipivoxil Treatment , 2007, Antiviral therapy.
[9] J. Pawlotsky,et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. , 2007, Journal of hepatology.
[10] A. Cross,et al. [781] FOUR YEAR ASSESSMENT OF ETV RESISTANCE IN NUCLEOSIDE-NAIVE AND LAMIVUDINE REFRACTORY PATIENTS , 2007 .
[11] J. Villeneuve,et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. , 2007, Journal of hepatology.
[12] C. Mazzucco,et al. Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.
[13] C. Mazzucco,et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B , 2006, Hepatology.
[14] George Kitis,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.
[15] J. Villeneuve,et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. , 2006, Gastroenterology.
[16] T. Berg,et al. Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy , 2006, Hepatology.
[17] Huiling Yang,et al. In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents , 2006, Antiviral therapy.
[18] Angeline Bartholomeusz,et al. HBV drug resistance: mechanisms, detection and interpretation. , 2006, Journal of hepatology.
[19] J. Pawlotsky,et al. Dynamics of Hepatitis B Virus Resistance to Lamivudine , 2006, Journal of Virology.
[20] J. Pawlotsky. The concept of hepatitis B virus mutant escape. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[21] P. Colson,et al. Unusual Selection of Rta181V Hbv Mutants Cross-Resistant to Adefovir following Prolonged Lamivudine Monotherapy: Report of Two Cases , 2005, Antiviral therapy.
[22] J. Villeneuve,et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir , 2005, Hepatology.
[23] T. Berg,et al. Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection , 2004, Hepatology.
[24] P. Angus,et al. Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.
[25] E. Keeffe,et al. Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.
[26] C. Gibbs,et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.
[27] Michael D. Miller,et al. The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.
[28] Angeline Bartholomeusz,et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.
[29] M. Wulfsohn,et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B , 2003, Hepatology.
[30] F. Zoulim,et al. Inhibitory activity of dioxolane purine analogs on wild‐type and lamivudine‐resistant mutants of hepadnaviruses , 2002, Hepatology.
[31] C. Gibbs,et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks , 2002, Hepatology.
[32] F. Zoulim,et al. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance , 1999, Hepatology.
[33] K. Walters,et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .
[34] Y. Cheng,et al. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. , 1998, Biochemical pharmacology.